Literature DB >> 7205627

Disposition of furosemide in functionally hepatectomized dogs.

R K Verbeeck, J F Gerkens, G R Wilkinson, R A Branch.   

Abstract

To assess the role of the liver in the elimination of furosemide, the disposition kinetics of the diuretic after intravenous administration were studied in dogs with total devascularization of the liver and sham-operated animals. Functional hepatectomy caused no significant changes in either the renal or the nonrenal clearances of furosemide; renal = 124.2 +/- 27.1 (mean +/- SE) and 106.6 +/- 17.5 ml/min and nonrenal = 148.2 +/- 11.4 and 112.6 +/- 21.0 ml/min in sham-operated and hepatectomized dogs, respectively. Devascularization of the liver had no effect on the plasma binding of furosemide which was 90.0% in the sham-operated and 88.2% in the hepatectomized animals. The steady-state volume of distribution of furosemide was relatively small, 0.70 +/- 0.09 liters/kg in control dogs and hepatectomy resulted in a reduction in this volume (0.58 +/- 0.09 liters/kg). This indicates that the liver is a significant organ for distribution of furosemide in the dog. Urinary recoveries of parent drug (43.2% of the dose in sham-operated dogs ad 49.1% in hepatectomized animals) and of its glucuronide (4.3% in sham-operated and 5.5% in hepatectomized dogs) were not influenced by hepatic devascularization. These findings demonstrate that, although nonrenal clearance accounts for about 50% of the elimination of furosemide, the liver does not play a significant role in this process in the dog.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7205627

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

Review 1.  Diuretics in pediatrics : current knowledge and future prospects.

Authors:  Maria M J van der Vorst; Joana E Kist; Albert J van der Heijden; Jacobus Burggraaf
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 2.  Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part II).

Authors:  L L Ponto; R D Schoenwald
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

3.  Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism.

Authors:  M G Lee; W L Chiou
Journal:  J Pharmacokinet Biopharm       Date:  1983-12

4.  Extrahepatic metabolism of frusemide in anaesthetized rabbits.

Authors:  J Vergés; L Héroux; H Maurice; P du Souich
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

5.  Furosemide dynamics in conscious rabbits: modulation by angiotensin II.

Authors:  W Homsy; S Marleau; P du Souich
Journal:  Cardiovasc Drugs Ther       Date:  1995-04       Impact factor: 3.727

6.  Furosemide dynamics in conscious rabbits: modulation by arginine vasopressin.

Authors:  R Babini; P du Souich
Journal:  Cardiovasc Drugs Ther       Date:  1995-04       Impact factor: 3.727

7.  Biotransformation of furosemide in kidney transplant patients.

Authors:  D E Smith; L Z Benet
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 8.  Furosemide pharmacokinetics and pharmacodynamics in health and disease--an update.

Authors:  M Hammarlund-Udenaes; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1989-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.